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ABSTRACT 
Polycythemia vera (PV), and essential thrombocythemia (ET) patients are characterized by 
an increased incidence of arterial and venous thromboses. To prevent vascular events is one of 
the most important challenges in the disease management, as thrombosis could be responsible 
for the morbidity and mortality in many cases. Since thrombosis can be an early complication of 
MPNs, an effective antithrombotic strategy has to be started as soon as the disease is diagnosed. 
Beside the use of appropriate medical therapies and preventive measures against cardiovascular 
risk factors, a healthy lifestyle may also have importance in MPNs, as it has already been 
accepted in the general population. However, it has not been accepted yet in the treatment of 
neoplasms, according to the general notion, thrombosis is "caused" by the disease rather than by 
the interplay of various factors. The relation between the disease and the thrombotic events is 
indisputable, though the role of the neoplasm accompanied by other diseases such as diabetes 
mellitus, cardiovascular diseases, or unhealthy life style, obesity, and smoking should be 
mentioned as addictive factors in case of myeloproliferative neoplasms thus increasing the 
susceptibility to developing a thrombosis. In this short communication, according to relevant 
medical literature, the author describes her concerns if cardiovascular diseases may be prevented 
by eliminating modifiable risk factors, and following a healthy diet, healthy life style and 
controlling body weight, and whether it may have an important benefit in the successful 
management of MPN patients. Should we apply the “medical nutrition therapy” consciously in 
the most appropriate and effective antithrombotic strategy? 
1. INTRODUCTION 
Philadelphia Chromosome “negative” myeloproliferative neoplasms (MPN) is a diverse 
group of hematological malignancies. MPNs are characterized by stem cell-derived 
clonal myeloproliferation primarily characterized by erythrocytosis and thrombocytosis 
with predisposition to thrombosis, bleeding, and the possibility of leukemic 
transformation. Polycythemia vera (PV) and essential thrombocythemia (ET) patients 
are characterized by an increased incidence of arterial and venous thromboses and by 
microcirculatory disturbances which often manifest in the diagnosis or in the preclinical 
phase of the disease. (Michiels, Abels et al. 1985) To prevent a significant number of 
early vascular events is still one of the most important challenges in the disease 
management, because thrombosis could be a major cause of morbidity and mortality in 
patients in many cases. (Tefferi 2012) Thus an effective antithrombotic strategy has to 
be started as soon as the disease is diagnosed. According to the international protocols, 
this strategy mostly includes treatment in different combination of low-dose aspirin, 
clopidogrel bisulfate, hydroxyurea, and interferon therapy. Phlebotomy also could be 
used accordingly as a risk adapted decision. (Vladareanu 2010) 
2. SUMMARY OF THE RELEVANT LITERATURE 
Several epidemiological studies performed in the field of the nutrition and physical 
activity of the general population are predictors of age-specific mortality and 
cardiovascular events. The connection between cardiovascular risk factors and 
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thrombosis is not doubted any more, and the identification and appropriate management 
of cardiovascular risk factors, the promotion of a healthy lifestyle in the general 
population have become important and popular. According to the World Heart 
Federation’s opinion: (Bas, Altan et al. 2005;Poirier, Giles et al. 2006Waskiewicz, 
Piotrowski et al. 2008) ”The role of diet is crucial in the development and prevention of 
cardiovascular diseases. Diet is one of the key things you can change that will impact all 
other cardiovascular risk factors.” Table 1 introduces the modifiable risk factor which 
could be important according to the World Heart Federation’s opinion. 
Table 1.  Risk factors associated with coronary heart disease and stroke according 
to the World Heart Federation 
 
Modifiable risk factors Non-modifiable risk factors 
Hypertension  Age 
Abnormal blood lipid levels Gender 
Tobacco Ethnicity  
Physical inactivity  
Family history of 
cardiovascular diseases  
Type 2 diabetes   
Diet high in saturated fat    
Chronically stressful life   
Social isolation   
Anxiety and depression    
Contraceptive pills    
Hormone replacement therapy    
Source: World Heart Federation (2012) 
But what about patients with MPNs? Does diet have as important a role as in the general 
population? On the contrary, the importance of a healthy lifestyle is frequently 
misjudged in MPN patients due to the tendency to consider thrombosis as it has been 
”caused” by the disease rather than by the interplay of various factors. ECLAP is a 
randomized trial (European Collaboration on Low-dose Aspirin in Polycythemia Vera ), 
which has many observations to support the idea that besides the basic medical 
antithrombotic strategy, we have to focus  more on the modifiable risk factors in MPN 
patients as well. According to the publication of Finazzi G. in 2004, the cumulative 
incidence rate of cardiovascular events (i.e., cardiovascular death and non-fatal 
thrombotic events) was 5.5 events/100 persons per year. The main cause of death was 
thrombosis. Their results showed that the two most important predictors of 
cardiovascular events were age (higher than 65 years) and positive history of 
thrombosis. Nevertheless, they have found smoking, hypertension and congestive heart 
failure to be further significant risk factors for thrombosis.(Finazzi 2004) In the same 
trial in 2007,  Landolfi et al. also described smoking as a habit that had an important 
effect on vascular risk associated with a significantly higher risk of arterial thrombotic 
events, and not just in the general population but among PV patients as well. A similar 
finding had been reported also in ET subjects by Besses et al. in 1999 and Jantunen in 
2001. (Besses, Cervantes et al. 1999; Jantunen, Juvonen et al. 2001) Additionally, the 
ECLAP observational study has shown that diabetes was a possible predictor of survival 
and cardiovascular mortality in MPN patients. According to the above mentioned 
studies, it is supposed that arterial hypertension, hypercholesterolemia, obesity and 
metabolic syndrome, the well-known major risk factors for the development of 
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cardiovascular diseases in the general population, could have an important role as the 
predictors of thrombosis in MPN patients despite the limited results. But surprisingly, 
we could find publications which rather contradicted the above mentioned notions. A 
few clinicians like Besses have found that ET patients demonstrated the independent 
contribution of hypercholesterolemia in predicting thrombosis. (Besses, Cervantes et al. 
1999) According to the relevant literature, the efficacy of statins in MPNs has yet to be 
tested in prospective studies, but their possible use in MPNs deserves clinical and 
scientific attention. In the view of nutrition, epidemiological studies and clinical trials 
indicate the importance of nutrition. In a prospective study, over 12 years, 14,962 
middle-aged adults participating in the Atherosclerosis Risk in Communities Study were 
followed up for incident VTE. According to their conclusion, it could be supposed that 
diet including more plant food and fish, and less red and processed meat could be 
associated with a lower incidence of venous thromboembolism. (Lichtenstein, Appel et 
al. 2006) The very long chain n-3 fatty acids lower the thrombotic tendency and risk of 
heart diseases. Other polyunsaturated fats and monounsaturated fat appear to have 
antithrombotic properties, but further studies are needed to reveal it. (Lands, Libelt et al. 
1992) Low intake of folate, vitamin B12, and vitamin B6 predispose patients to 
hyperhomocysteinemia, and the benefits of their supplementation in decreasing vascular 
diseases are under investigation.(Erzin, Uzun et al. 2008) Dietary flavonoids like 
apigenin and luteolin, and isoflavones like genistein appear to inhibit platelet 
aggregation only in pharmacological concentrations. (Clair and Anthony 2005) (Liu, 
Xing et al. 2006) Among the group of flavonoids, apigenin is very interesting as 
Navarro-Nunez L’s results demonstrate a clear increase in the ex vivo antiplatelet effect 
of aspirin in the presence of apigenin, which encourages the idea of the combined use of 
aspirin and certain flavonoids in patients, in whom aspirin fails to properly suppress the 
TxA(2) pathway. (Navarro-Nunez, Lozano et al. 2008) As we can see, diet presents an 
interesting area for research also in the field of general medicine, but work is indicated 
before specific recommendations are made. (Allman-Farinelli and Dawson 2005) 
According to the relevant literature in myeloproliferative neoplasms, the suspected 
factors could play an important role in the development of thrombosis in MPN patients, 
as a conclusion showed in Table 2.  
 Table 2. Factors that are suspected to play an important role in the development of 
thrombosis in MPN patients 
 
Source: World Heart Federation (2012) 
Disease related abnormalities Cardiovascular risk factors 
Hyperviscosity Obesity 
Leukocyte abnormality Diabetes 
Platelet abnormality Hypertension 
Inflammation  Smoking 
JAK2 V617F mutation Unhealthy diet 
Other factors Lack of physical activity 
Previous thrombosis   
Age   
Gender   
Other genetic mutations   
Other unknown factors, local, general triggers   
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3. CONCLUSIONS 
The American Dietetic Association introduced a new aim in 2010, the goal of which is 
the integration of ”Medical Nutrition Therapy (MNT) and Pharmacotherapy” and 
introduced many guidelines as in diabetes mellitus, summarizing the evidence for the 
effectiveness of MNT in preventing and treating diabetes, and providing physicians with 
information on how to refer patients to MNT. The initiation and ongoing use of medical 
therapy is essential in myeloproliferative patients to prevent the development of disease 
complications and to manage the disease appropriately. As the life expectancy of 
patients in adequate condition is very promising, the survival years can reach up to 
several decades. Although the most frequent cause of death is patients is thrombosis, it is 
an interesting question whether conscious life style of these patients can lead to the 
achievement of a more beneficial therapy and whether thrombotic events may be 
prevented to a certain extent (parallel to medical therapy), thus achieving a longer life 
span. Conscious, healthy nutrition has an unequivocal role in preserving vascular 
intactness, and therefore, further investigation is needed in this topic. It is also vital to 
encourage patients to follow a healthy lifestyle. Nevertheless, its possible use in MPNs 
deserves clinical and scientific attention. Therefore, diet as one of the environmental 
factors has an impact on the development of thrombosis and hemostasis, and 
macronutrients, micronutrients, and other bioactive food components may alter the 
predisposition to thrombosis. However, in many cases such as the management of 
diabetes, the evidence is strong that medical nutrition therapy provided by registered 
dietitians is an effective and essential therapy, but in MPN neoplasms no strong evidence 
has been established yet. Though according to the known details, this notion should not 
be neglected, especially in the view of controlling risk factors. 
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